Bio-Path | 10-Q: FY2025 Q2 EPS: USD -0.55

LB filings

2025.08.14 21:06

I'm PortAI, I can summarize articles.

EPS: As of FY2025 Q2, the actual value is USD -0.55.

Research and Development Expense: For the three months ended June 30, 2025, research and development expenses were $4.0 million, an increase of $2.2 million compared to the same period in 2024. For the six months ended June 30, 2025, expenses were $6.0 million, an increase of $1.9 million compared to the same period in 2024.
General and Administrative Expense: For the three months ended June 30, 2025, general and administrative expenses were $0.5 million, a decrease of $0.7 million compared to the same period in 2024. For the six months ended June 30, 2025, expenses were $1.8 million, a decrease of $0.8 million compared to the same period in 2024.

Net Loss: For the three months ended June 30, 2025, the net loss was $4.6 million, an increase of $2.7 million compared to the same period in 2024. For the six months ended June 30, 2025, the net loss was $7.4 million, a decrease of $2.4 million compared to the same period in 2024.

Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used in operating activities was $1.6 million, compared to $4.3 million for the same period in 2024.
Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided by financing activities was $0.4 million, compared to $7.2 million for the same period in 2024.

Operational Pause: On June 24, 2025, Bio-Path Holdings, Inc. announced an operational pause to conserve capital, furloughing most employees while seeking financing or additional capital.
Clinical Trials: The company is focusing on the development of its lead drug candidate, Prexigebersen, in combination therapies for AML, with ongoing Phase 2 clinical trials.
Capital Requirements: The company expects to continue incurring significant operating expenses and requires substantial additional capital to fund its projected operating requirements.